Insulin Resistance Linked to 12 Cancer Types: AI Model Reveals Risk

Insulin resistance – the body’s diminished ability to respond to insulin, a hormone crucial for regulating blood glucose – is a hallmark of type 2 diabetes. Beyond its well-established link to diabetes, insulin resistance is increasingly recognized as a contributing factor to cardiovascular disease, kidney disease, and liver ailments. Now, a groundbreaking study utilizing artificial intelligence has revealed a significant association between insulin resistance and an elevated risk of developing 12 different types of cancer.

For years, researchers have suspected a connection between insulin resistance and cancer development, but establishing definitive evidence has proven challenging. The complexity of the human body makes it difficult to isolate causal relationships between physiological processes and disease. To overcome this hurdle, a team led by Yuta Hiraike, a researcher from the University of Tokyo Hospital, developed an innovative machine learning tool called AI-IR. This tool predicts insulin resistance based on nine readily available clinical parameters obtained during routine health checkups.

“We recently made a tool, AI-IR, for predicting insulin resistance in individuals based on nine different pieces of medical information. It proved successful and made us think we could apply this tool to related concerns,” explained Hiraike. “While a possible link between insulin resistance and cancer has been suggested, large-scale evidence has been limited due to the difficulty of evaluating insulin resistance in the clinic. But with AI-IR, we have provided the first population-scale evidence that insulin resistance is a risk factor for cancer. And since the nine input parameters for AI-IR are obtained through standard health checkups, AI-IR could be easily implemented to identify high-risk individuals and enable focused screening of diabetes, cardiovascular disease and cancer.”

The study, published in Nature Communications, analyzed data from approximately 500,000 participants in the UK Biobank. The findings demonstrated that AI-IR accurately predicted insulin resistance and was significantly associated with an increased risk of six cancers: uterine, kidney, esophagus, pancreas, colon, and breast. Nominal associations were also observed with six additional cancers, including renal pelvis, small intestine, stomach, liver and gallbladder, leukemia, and bronchial and lung cancers.

Currently, body mass index (BMI) is often used to estimate an individual’s insulin resistance and potential cancer risk. However, BMI has limitations. It can produce false positives, identifying metabolically healthy obese individuals as high-risk, and false negatives, failing to identify insulin resistance in individuals with a normal BMI. AI-IR offers a more nuanced assessment, potentially detecting insulin resistance that BMI alone might miss.

Hiraike and his team faced the challenge of convincing the scientific community of AI-IR’s reliability and reproducibility. They successfully demonstrated not only the model’s predictive power but also its robustness under various conditions. “When compared with directly measured insulin resistance in validation datasets, AI-IR achieved strong predictive performance,” Hiraike stated. “Directly measuring insulin resistance is impractical except where patients are treated in specialized diabetes clinics. AI-IR provides a robust and scalable alternative for evaluating insulin resistance at the population scale. By combining nine clinical parameters into a single metric, AI-IR can detect insulin resistance that BMI alone cannot explain. We are now working to understand how genetic differences between individuals influence this risk, and ultimately to link large-scale human data with molecular biology studies to develop better strategies to overcome insulin resistance.”

The researchers found that individuals with higher AI-IR scores had a 25% increased risk of developing composite cancers – groups of cancers whose risks increase with insulin resistance – compared to those with lower scores. Importantly, AI-IR’s ability to predict these composite cancers was comparable to that of metabolic syndrome and the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL) ratio, and even surpassed the predictive power of BMI and the triglyceride-glucose (TyG) index.

This research highlights the importance of addressing insulin resistance as a potential modifiable risk factor for cancer. While further investigation is needed to fully elucidate the underlying mechanisms linking insulin resistance to cancer development, the findings suggest that early identification and management of insulin resistance could play a crucial role in cancer prevention and screening strategies. The ease of implementation of AI-IR, utilizing standard health checkup parameters, offers a promising avenue for identifying individuals at increased risk and tailoring preventative interventions.

The study underscores the growing role of machine learning in medical research, offering new tools to unravel complex biological relationships and improve patient care. As Hiraike and his team continue to refine AI-IR and explore the genetic factors influencing insulin resistance, the potential for personalized cancer prevention strategies becomes increasingly tangible.